Structure and binding kinetics of three different human CD1d-α-agalactosylceramide-specific T cell receptors

被引:77
作者
Gadola, SD
Koch, M
Marles-Wright, J
Lissin, NM
Shepherd, D
Matulis, G
Harlos, K
Villiger, PM
Stuart, DI
Jakobsen, BK
Cerundolo, V
Jones, EY
机构
[1] Canc Res UK Receptor Struct Res Grp, Oxford OX3 7BN, England
[2] Avidex, Abingdon OX14 4RX, Oxon, England
[3] Univ Bern, Inselspital, Dept Rheumatol & Clin Immunol, CH-3010 Bern, Switzerland
[4] Univ Oxford, Nuffield Dept Med, Weatherall Inst Mol Med, Canc Res UK Tumor Immunol Grp, Oxford OX3 9DS, England
基金
英国医学研究理事会;
关键词
D O I
10.1084/jem.20052369
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Invariant human TCR V alpha 24-J alpha 18(+)/V beta 11+NKT cells (iNKT) are restricted by CD1d-alpha-glycosylceramides. We analyzed crystal structures and binding characteristics for an iNKT TCR plus two CD1d-alpha-GalCer-specific V beta 11(+) TCRs that use different TCR V alpha chains. The results were similar to those previously reported for MHC-peptide-specific TCRs, illustrating the versatility of the TCR platform. Docking TCR and CD1d-alpha-GalCer structures provided plausible insights into their interaction. The model supports a diagonal orientation of TCR on CD1d and suggests that complementarity determining region (CDR)3 alpha, CDR3 beta, and CDR1 beta interact with ligands presented by CD1d, whereas CDR2 beta. binds to the CD1d alpha 1 helix. This docking provides an explanation for the dominant usage of V beta 11 and V beta 8.2 chains by human and mouse iNKT cells, respectively, for recognition of CD1d-alpha-GalCer.
引用
收藏
页码:699 / 710
页数:12
相关论文
共 53 条
[1]   Canonical structures for the hypervariable regions of T cell αβ receptors [J].
Al-Lazikani, B ;
Lesk, AM ;
Chothia, C .
JOURNAL OF MOLECULAR BIOLOGY, 2000, 295 (04) :979-995
[2]   THE CCP4 SUITE - PROGRAMS FOR PROTEIN CRYSTALLOGRAPHY [J].
BAILEY, S .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1994, 50 :760-763
[3]  
BALK SP, 1991, J IMMUNOL, V146, P768
[4]   The crystal structure of human CD1b with a bound bacterial glycolipid [J].
Batuwangala, T ;
Shepherd, D ;
Gadola, SD ;
Gibson, KJC ;
Zaccai, NR ;
Fersht, AR ;
Besra, GS ;
Cerundolo, V ;
Jones, EY .
JOURNAL OF IMMUNOLOGY, 2004, 172 (04) :2382-2388
[5]   Diverse CD1d-restricted T cells: diverse phenotypes, and diverse functions [J].
Behar, SM ;
Cardell, S .
SEMINARS IN IMMUNOLOGY, 2000, 12 (06) :551-560
[6]   Mouse CD1-specific NK1 T cells: Development, specificity, and function [J].
Bendelac, A ;
Rivera, MN ;
Park, SH ;
Roark, JH .
ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :535-562
[7]   Characterization of the early stages of thymic NKT cell development [J].
Benlagha, K ;
Wei, DG ;
Veiga, J ;
Teyton, L ;
Bendelac, A .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (04) :485-492
[8]   Stable, soluble T-cell receptor molecules for crystallization and therapeutics [J].
Boulter, JM ;
Glick, M ;
Todorov, PT ;
Baston, E ;
Sami, M ;
Rizkallah, P ;
Jakobsen, BK .
PROTEIN ENGINEERING, 2003, 16 (09) :707-711
[9]   MOUSE CD1 IS DISTINCT FROM AND COEXISTS WITH TL IN THE SAME THYMUS [J].
BRADBURY, A ;
BELT, KT ;
NERI, TM ;
MILSTEIN, C ;
CALABI, F .
EMBO JOURNAL, 1988, 7 (10) :3081-3086
[10]   CD1: Antigen presentation and T cell function [J].
Brigl, M ;
Brenner, MB .
ANNUAL REVIEW OF IMMUNOLOGY, 2004, 22 :817-890